Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

Logo
LH US​

Labcorp Holdings Inc.(LH US)

$328.95-0.980.30%Ext:$337.42+8.472.57%(Market Closed · 23:55:56 UTC)

Overview

Profile

Financials & Metrics

FinancialsChartingShort InterestEmployees

Labcorp Holdings Inc. — Company Profile

Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.

Sector
Health Care
Industry
Health Care Equipment & Supplies
Exchange
UN
CEO
Adam H. Schechter
Headquarters
Burlington, NC, US
IPO Date
Mar 29, 1990
Employees
71,000
Website
www.labcorp.com

Key Metrics

Price
$308.49
Market Cap
$25.30B
Revenue (TTM)
$3.54B
Net Income (TTM)
$277.80M
EPS (TTM)
3.37
P/E (TTM)
26.87
P/B (TTM)
2.90
Dividend Yield
110.74%
ROE (TTM)
3.18%
ROA (TTM)
1.46%
Operating Margin
10.95%
Beta
0.21

Dividends

Last Dividend
$0.72
Last Yield
1.11%

Summary

Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.

Website
www.labcorp.com
Location
Burlington, NC, US
Phone336 229 1127
Employees71,000
CEOAdam H. Schechter
Sector
Health Care
Industry
Health Care Equipment & Supplies
IPO DateMar 29, 1990

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

News

  • Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 202623 Oct
  • Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential22 Oct
  • LH vs. DHR: Which Stock Is the Better Value Option?22 Oct
  • Labcorp Prepares to Report Q3 Earnings: What's in the Cards?21 Oct
  • Labcorp Declares Quarterly Dividend21 Oct
  • Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp20 Oct
  • Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp20 Oct
  • Labcorp Holdings Inc. $LH Shares Sold by Birch Hill Investment Advisors LLC18 Oct
  • OPKO Health to Sell Select BioReference Assets to Labcorp for $722M16 Oct
  • OPKO Health Sheds Diagnostics Businesses in Major Labcorp Deal15 Oct
  • Three stocks poised to beat estimates this earnings season15 Oct
  • Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health15 Oct
  • Labcorp and Arianna Huffington's Thrive Global Collaborate to Launch Thrive 5 Health Test13 Oct
  • Here's Why Labcorp Holdings (LH) is a Strong Value Stock6 Oct
  • Labcorp to Announce Third Quarter 2026 Financial Results on October 28, 202630 Sep
  • Is This the Right Time to Add Labcorp Stock to Your Portfolio?29 Sep
  • Labcorp (NYSE:LH) Shares Gap Down – Should You Sell?24 Sep
  • Critical Survey: HCA Healthcare (NYSE:HCA) and Labcorp (NYSE:LH)24 Sep
  • Labcorp: The CMS Selloff Represents An Excellent Opportunity - Strong Buy23 Sep
  • Labcorp's Future Driven By Clinical Testing Demand, Despite Impact From Medicare Cuts22 Sep

Key Stats

Trading

Px/Chg 1D$308.49 / +1.28%
Avg Volume630.24K
Beta0.21
Mkt Cap25.30B
FD Mkt Cap27.44B

Float

Shrs Out/Float82.00M / 81.67M
Short Float0.03%
Days to Cover3.80
Stock Repurchased$98.00M

Current Valuation

EV31.57B
EV/EBITDA15.31
EV/Sales2.23
P/B2.90
P/S1.79
FCF Yield0.28%
ROE3.18%
ROA1.46%
Current Ratio1.73

Dividend

Cash$0.72
Yield110.74%
Yield (TTM)110.74%

Estimates

P/E26.87
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgMay '23Apr '24Apr '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings60.2813.8342.5425.82128.1591.06
Price / Sales3.521.491.461.486.007.15
Price / Book Value2.351.752.262.392.452.90
Price / Free Cash Flow90.3612.0020.3417.5843.05358.81
ENTERPRISE VALUE METRICS
Enterprise Value26,250.323,630.923,216.125,031.827,800.031,572.6
Enterprise Value / Sales4.531.991.911.927.918.92
Enterprise Value / EBITDA33.4312.0917.2013.8266.4157.60
Enterprise Value / EBIT53.1516.6730.2121.44113.1984.24

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue1.5%13,136.111,863.912,161.613,008.913,951.7
Gross Income-7%4,992.43,708.93,364.93,624.43,732.5
EBITDA-14%3,676.41,954.41,349.41,811.32,012.7
EBIT-19%3,099.41,417.2768.51,167.81,331.6
Net Income-22.1%2,377.31,279.1418.0746.0876.5
EPS (Diluted)-19.1%24.3813.964.778.8410.46
BALANCE SHEET
Cash & ST Inv-22.5%1,472.7320.6536.81,518.7532.3
Total Assets-2.5%20,385.420,155.116,725.118,379.018,392.7
Total Liabilities-84.1%10,091.410,039.68,834.610,312.59,756.0
Total Shareholder Equity-4.3%10,273.410,096.67,875.08,052.28,619.8
CASH FLOW
Net Operating Cash Flow-14.8%3,109.61,955.91,327.71,585.81,640.5
Cap Ex-1.4%-460.4-481.9-453.6-489.9-434.5
Free Cash Flow-17.9%2,649.21,474.0874.11,095.91,206.0

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)330.00
Basic Shares82.00
Market Cap27,059.6
Diluted Shares82.90
Fully Diluted Shares Outstanding82.90
Fully Diluted Market Cap27,356.6
+Consolidated Debt7,240.6
−In-the-Money Convertible Debt—
+Capital Leases906.5
+Operating Leases—
−Cash & Equivalents-981.1
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest16.9
+Pension Liabilities—
Enterprise Value33,336.0

Segment data

Revenue

by Products and services

  • Labcorp Diagnostics100%

Revenue

by Geography

  • North America81%
  • Europe13%
  • Other Countries6%

Related companies

WuXi AppTec Co., Ltd.

WUXAY US

Natera, Inc.

NTRA US

Guardant Health, Inc.

GH US

WuXi XDC Cayman Inc

2268 HK

Caris Life Sciences, Inc.

CAI US

Sonic Healthcare Ltd / ADR

SKHHY US

GRAIL, Inc.

GRAL US

Joinn Laboratories(China)Co.,Ltd.

603127 CG

RadNet, Inc.

RDNT US

Sotera Health Co

SHC US

Vontier Corp

VNT US

DiaSorin S.p.A.

DSRLF US